Department of Research, Comprehensive Cancer Centre North East, AH Groningen, The Netherlands.
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S64-73. doi: 10.1016/j.ejso.2010.05.026.
Aim of this study was to describe treatment patterns and outcome according to region, and according to hospital types and volumes among patients with colon cancer in the Netherlands.
All patients with invasive colon carcinoma diagnosed in the period 2001-2006 were selected from the Netherlands Cancer Registry. Logistic regression analyses were performed to examine the influence of relevant factors on the odds of having adequate lymph node evaluation, receiving adjuvant chemotherapy and postoperative mortality. Relative survival analysis was used to estimate relative excess risk of dying according to hospital type and volume.
In total, 39 907 patients were selected. Patients diagnosed in a university hospital had a higher odds (OR 2.47; 95% CI 2.19-2.78) and patients diagnosed in a hospital with >100 colon carcinoma diagnoses annually had a lower odds (OR 0.70; 95% CI 0.64-0.77) of having >/=10 lymph nodes evaluated. The odds of receiving adjuvant chemotherapy was lower in patients diagnosed in teaching hospitals (OR 0.85; 95% CI 0.73-0.98) and university hospitals (OR 0.56; 95% CI 0.45-0.70) compared to patients diagnosed in non-teaching hospitals. Funnel plots showed large variation in these two outcome measures between individual hospitals. No differences in postoperative mortality were found between hospital types or volumes. Patients diagnosed in university hospitals and patients diagnosed in hospitals with >50 diagnoses of colon carcinoma per year had a better survival.
Variation in treatment and outcome of patients with colon cancer in the Netherlands was revealed, with differences between hospital types and volumes. However, variation seemed mainly based on the level of the individual hospital.
本研究旨在描述荷兰结肠癌患者的治疗模式和结局,以及按地区、医院类型和规模的差异。
从荷兰癌症登记处选择 2001-2006 年期间诊断为浸润性结肠癌的所有患者。采用逻辑回归分析,检验相关因素对充分淋巴结评估、接受辅助化疗和术后死亡率的影响。相对生存分析用于估计按医院类型和规模划分的死亡相对风险超额。
共选择了 39907 例患者。在大学医院诊断的患者(OR 2.47;95%CI 2.19-2.78)和每年诊断>100 例结肠癌的医院(OR 0.70;95%CI 0.64-0.77)的可能性更高有>/=10 个淋巴结被评估。与在非教学医院诊断的患者相比,在教学医院(OR 0.85;95%CI 0.73-0.98)和大学医院(OR 0.56;95%CI 0.45-0.70)诊断的患者接受辅助化疗的可能性较低。漏斗图显示这些两种结局指标在个别医院之间存在较大差异。在医院类型或规模之间未发现术后死亡率的差异。在大学医院诊断的患者和每年诊断>50 例结肠癌的医院诊断的患者的生存情况较好。
揭示了荷兰结肠癌患者治疗和结局的差异,存在医院类型和规模的差异。然而,这种差异似乎主要基于单个医院的水平。